CEO statement

Idiopathic pulmonary fibrosis is a condition that robs patients of their ability to breathe. The associated cough can have a profound impact on the patient’s quality of life, affecting work, sleep, and personal relationships.

We have a strong strategic commitment in dedicating ourselves to fibrotic lung diseases, including diffuse systemic sclerosis (dSSc), and to bring truly life-changing medicines to patients. This means that we listen to the patient and find out how the disease impairs their life. It is so important for us to understand and respect those experiences and to build those insights into our development programmes. This will help expedite the progress of our medicines to regulators, payers, and ultimately patients.

We are proud of our complementary pipeline. VP01 has been shown preclinically to work through multi-modal pathways, which may benefit complex diseases such as IPF and dSSc. A phase II study in dSSc started in December and we are now in the process of finalizing the documentation for a CTA submission for the phase II study in IPF. VP02 is a new formulation of an existing pharmaceutically active medicine, and is currently in the preclinical stage. We are on target to enter clinical development with VP02 in 2020.

Our company’s distinctive approach springs from our collaborative nature and deep roots in world-class science. As one of the potential leaders in the treatment of fibrotic lung diseases, we are committed to bringing these transformational medicines to patients.